A detailed history of Jennison Associates LLC transactions in Innoviva, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 66,056 shares of INVA stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,056
Previous 103,227 36.01%
Holding current value
$1.18 Million
Previous $1.69 Million 24.7%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$16.33 - $20.04 $607,002 - $744,906
-37,171 Reduced 36.01%
66,056 $1.27 Million
Q2 2024

Aug 05, 2024

BUY
$14.4 - $16.4 $370,584 - $422,053
25,735 Added 33.21%
103,227 $1.69 Million
Q1 2024

May 02, 2024

BUY
$14.56 - $16.78 $513,880 - $592,233
35,294 Added 83.64%
77,492 $1.18 Million
Q4 2023

Feb 01, 2024

SELL
$12.32 - $16.27 $528,195 - $697,543
-42,873 Reduced 50.4%
42,198 $676,000
Q3 2023

Oct 31, 2023

BUY
$12.37 - $13.89 $438,269 - $492,122
35,430 Added 71.37%
85,071 $1.11 Million
Q2 2023

Aug 03, 2023

BUY
$11.39 - $13.72 $565,410 - $681,074
49,641 New
49,641 $631,000
Q4 2022

Feb 09, 2023

SELL
$11.8 - $13.78 $240,153 - $280,450
-20,352 Reduced 21.62%
73,801 $977,000
Q3 2022

Nov 01, 2022

BUY
$11.61 - $15.22 $14,164 - $18,568
1,220 Added 1.31%
94,153 $1.09 Million
Q2 2022

Aug 02, 2022

SELL
$14.32 - $19.88 $1,245 - $1,729
-87 Reduced 0.09%
92,933 $1.37 Million
Q1 2022

May 11, 2022

SELL
$15.39 - $20.25 $509,993 - $671,044
-33,138 Reduced 26.27%
93,020 $1.8 Million
Q4 2021

Feb 08, 2022

BUY
$15.91 - $18.72 $823,215 - $968,610
51,742 Added 69.53%
126,158 $2.18 Million
Q3 2021

Nov 09, 2021

BUY
$13.06 - $17.24 $971,872 - $1.28 Million
74,416 New
74,416 $1.24 Million

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.24B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Jennison Associates LLC Portfolio

Follow Jennison Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.